B. Metzler seel. Sohn & Co. AG Increases Stock Holdings in Merck & Co., Inc. $MRK

B. Metzler seel. Sohn & Co. AG raised its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 4.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 465,812 shares of the company's stock after purchasing an additional 18,602 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Merck & Co., Inc. were worth $49,086,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. DLD Asset Management LP boosted its holdings in shares of Merck & Co., Inc. by 30.1% in the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company's stock worth $3,986,675,000 after buying an additional 11,000,000 shares during the last quarter. Legal & General Group Plc raised its holdings in Merck & Co., Inc. by 5.9% in the 3rd quarter. Legal & General Group Plc now owns 20,659,157 shares of the company's stock worth $1,733,923,000 after purchasing an additional 1,156,112 shares during the period. Invesco Ltd. raised its holdings in Merck & Co., Inc. by 16.6% in the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company's stock worth $1,665,585,000 after purchasing an additional 2,821,766 shares during the period. Ameriprise Financial Inc. lifted its position in Merck & Co., Inc. by 20.7% during the third quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company's stock valued at $1,336,877,000 after purchasing an additional 2,735,459 shares in the last quarter. Finally, Nordea Investment Management AB lifted its position in Merck & Co., Inc. by 2.0% during the third quarter. Nordea Investment Management AB now owns 10,945,187 shares of the company's stock valued at $876,600,000 after purchasing an additional 209,759 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company's stock.

Analyst Ratings Changes

A number of brokerages have commented on MRK. Wells Fargo & Company upped their price target on Merck & Co., Inc. from $135.00 to $150.00 and gave the stock an "overweight" rating in a research report on Thursday, March 12th. Citigroup lifted their price objective on Merck & Co., Inc. from $120.00 to $125.00 and gave the company a "neutral" rating in a research report on Friday, March 20th. Guggenheim boosted their price objective on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a "buy" rating in a research note on Friday, February 6th. Wall Street Zen raised shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating in a report on Saturday, March 28th. Finally, Cantor Fitzgerald raised their target price on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $128.47.

Insider Buying and Selling

In other news, CFO Caroline Litchfield sold 41,997 shares of Merck & Co., Inc. stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $119.61, for a total transaction of $5,023,261.17. Following the sale, the chief financial officer owned 90,192 shares in the company, valued at $10,787,865.12. This trade represents a 31.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CMO Chirfi Guindo sold 20,000 shares of the business's stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $121.88, for a total transaction of $2,437,600.00. Following the completion of the transaction, the chief marketing officer directly owned 80,615 shares in the company, valued at $9,825,356.20. This trade represents a 19.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 320,176 shares of company stock worth $38,281,735 in the last quarter. 0.13% of the stock is owned by insiders.

Merck & Co., Inc. Trading Up 0.3%

Shares of MRK stock opened at $112.87 on Thursday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.30 and a current ratio of 1.54. The stock has a fifty day simple moving average of $118.89 and a two-hundred day simple moving average of $106.53. The firm has a market capitalization of $278.77 billion, a PE ratio of 15.50, a PEG ratio of 2.26 and a beta of 0.26. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $125.14.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $2.01 by $0.03. The business had revenue of $16.40 billion for the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business's revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the business earned $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, analysts predict that Merck & Co., Inc. will post 4.93 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Investors of record on Monday, March 16th were issued a $0.85 dividend. The ex-dividend date of this dividend was Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 3.0%. Merck & Co., Inc.'s payout ratio is currently 46.70%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Announced a multi‑year partnership with Google Cloud valued at up to $1 billion to deploy agentic AI across R&D, manufacturing and commercial functions — a potential productivity and R&D acceleration catalyst that could improve long‑term margins and pipeline efficiency. Merck to partner with Google Cloud on AI initiatives
• Positive Sentiment: FDA approved Merck’s once‑daily IDVYNSO (doravirine/islatravir) for HIV-1 — a new oral two‑drug regimen that expands Merck’s infectious‑disease franchise and provides near‑term commercial upside. FDA Approves Merck's Once-Daily IDVYNSO
• Positive Sentiment: Won EU approval for ENFLONSIA to protect infants from RSV — another regulatory win that supports near‑term revenue diversification in vaccines. Merck Wins EU Approval for ENFLONSIA
• Neutral Sentiment: Reported interest in Inhibrx’s Keytruda‑linked experimental cancer drug from multiple buyers including Merck — potential M&A optionality but uncertain timing/value. Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug
• Neutral Sentiment: Market report flags increasing competition in polycythemia vera with several entrants (including Merck’s bomedemstat) in development — underscores both addressable market growth and increasing competitive risk over the next decade. Polycythemia Vera Market Set for Transformation
• Negative Sentiment: Merck and Eisai said the Phase 3 LITESPARK‑012 combination in first‑line advanced renal cell carcinoma failed to meet primary endpoints — a notable clinical setback that reduced near‑term oncology upside and pushed shares lower in recent sessions. Merck‑Eisai's combination cancer therapy fails meet main goals
• Negative Sentiment: Market coverage highlights the stock decline after the kidney‑cancer trial miss, reflecting investor concern over Keytruda‑combination setbacks even as Keytruda remains a major revenue driver. MRK Down as Triplet Therapy Fails to Meet Goal

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.